CA2420717C - Artificial intelligence system for genetic analysis - Google Patents
Artificial intelligence system for genetic analysis Download PDFInfo
- Publication number
- CA2420717C CA2420717C CA2420717A CA2420717A CA2420717C CA 2420717 C CA2420717 C CA 2420717C CA 2420717 A CA2420717 A CA 2420717A CA 2420717 A CA2420717 A CA 2420717A CA 2420717 C CA2420717 C CA 2420717C
- Authority
- CA
- Canada
- Prior art keywords
- information
- patient
- hybridization
- data
- living organism
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000013473 artificial intelligence Methods 0.000 title claims abstract description 45
- 238000012252 genetic analysis Methods 0.000 title description 4
- 238000009396 hybridization Methods 0.000 claims abstract description 99
- 238000012545 processing Methods 0.000 claims abstract description 74
- 238000012360 testing method Methods 0.000 claims abstract description 54
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 52
- 238000011282 treatment Methods 0.000 claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 36
- 238000004458 analytical method Methods 0.000 claims abstract description 34
- 230000003287 optical effect Effects 0.000 claims abstract description 19
- 230000014509 gene expression Effects 0.000 claims description 54
- 239000000523 sample Substances 0.000 claims description 50
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 40
- 201000010099 disease Diseases 0.000 claims description 39
- 230000004962 physiological condition Effects 0.000 claims description 29
- 230000006870 function Effects 0.000 claims description 28
- 230000002068 genetic effect Effects 0.000 claims description 26
- 238000002493 microarray Methods 0.000 claims description 25
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 23
- 238000003745 diagnosis Methods 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 238000004422 calculation algorithm Methods 0.000 claims description 15
- 238000012827 research and development Methods 0.000 claims description 12
- 238000011160 research Methods 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 5
- 238000007405 data analysis Methods 0.000 claims description 5
- 239000000758 substrate Substances 0.000 claims description 4
- 230000008520 organization Effects 0.000 claims description 3
- 238000003499 nucleic acid array Methods 0.000 abstract description 16
- 238000000018 DNA microarray Methods 0.000 abstract description 14
- 210000001519 tissue Anatomy 0.000 description 19
- 150000007523 nucleic acids Chemical class 0.000 description 16
- 230000035772 mutation Effects 0.000 description 15
- 238000013461 design Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- 102000039446 nucleic acids Human genes 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- 238000007726 management method Methods 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 230000001575 pathological effect Effects 0.000 description 9
- 238000003860 storage Methods 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 8
- 239000002157 polynucleotide Substances 0.000 description 8
- 102000040430 polynucleotide Human genes 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 238000004590 computer program Methods 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000012913 prioritisation Methods 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000013497 data interchange Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000002853 nucleic acid probe Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 101150072950 BRCA1 gene Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000013528 artificial neural network Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 235000003869 genetically modified organism Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 230000005055 memory storage Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000012775 microarray technology Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000012958 reprocessing Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 108700040618 BRCA1 Genes Proteins 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101000860852 Homo sapiens Coronin-1A Proteins 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011217 control strategy Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000013523 data management Methods 0.000 description 1
- 238000007418 data mining Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000004141 dimensional analysis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 230000008826 genomic mutation Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000007641 inkjet printing Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000013439 planning Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Theoretical Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Bioethics (AREA)
- Databases & Information Systems (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15125899P | 1999-08-27 | 1999-08-27 | |
| US60/151,258 | 1999-08-27 | ||
| PCT/US2000/023597 WO2001016860A2 (en) | 1999-08-27 | 2000-08-28 | Artificial intelligence system for genetic analysis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| CA2420717A1 CA2420717A1 (en) | 2001-03-08 |
| CA2420717E CA2420717E (en) | 2010-07-27 |
| CA2420717C true CA2420717C (en) | 2010-07-27 |
Family
ID=22537965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2420717A Expired - Fee Related CA2420717C (en) | 1999-08-27 | 2000-08-28 | Artificial intelligence system for genetic analysis |
Country Status (6)
| Country | Link |
|---|---|
| EP (2) | EP2899660A1 (https=) |
| JP (4) | JP2003508853A (https=) |
| AU (1) | AU785341B2 (https=) |
| CA (1) | CA2420717C (https=) |
| NZ (1) | NZ518022A (https=) |
| WO (1) | WO2001016860A2 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6990221B2 (en) | 1998-02-07 | 2006-01-24 | Biodiscovery, Inc. | Automated DNA array image segmentation and analysis |
| US7099502B2 (en) | 1999-10-12 | 2006-08-29 | Biodiscovery, Inc. | System and method for automatically processing microarrays |
| ATE526423T1 (de) | 2000-04-18 | 2011-10-15 | Virco Bvba | Verfahren zum messen des medikamentenwiderstands gegen hcv |
| FR2819915B1 (fr) * | 2001-01-19 | 2006-11-17 | Interactive Predictive Prevent | Procede pour traiter des donnees d'analyse biologique et systeme expert d'analyse biologique mettant en oeuvre ce procede |
| US7315784B2 (en) | 2001-02-15 | 2008-01-01 | Siemens Aktiengesellschaft | Network for evaluating data obtained in a biochip measurement device |
| JP2002318858A (ja) * | 2001-04-19 | 2002-10-31 | Toshitada Kameda | 医療計画作成支援システム及びコンピュータプログラム |
| US20020155587A1 (en) | 2001-04-20 | 2002-10-24 | Sequenom, Inc. | System and method for testing a biological sample |
| AU2002308662A1 (en) * | 2001-05-12 | 2002-11-25 | X-Mine, Inc. | Web-based genetic research apparatus |
| US6958211B2 (en) | 2001-08-08 | 2005-10-25 | Tibotech Bvba | Methods of assessing HIV integrase inhibitor therapy |
| JP2003099624A (ja) * | 2001-09-25 | 2003-04-04 | Toyo Kohan Co Ltd | Ｄｎａ提供システム |
| EP1329835A1 (en) * | 2002-01-22 | 2003-07-23 | Genonyme GmbH | Method and system for anonymously administrating medical test results and user-enabled health risk assessment |
| JP2004069559A (ja) | 2002-08-07 | 2004-03-04 | Seiko Epson Corp | 製造システム、その制御装置、制御方法、制御システム及び制御プログラム |
| US7512496B2 (en) | 2002-09-25 | 2009-03-31 | Soheil Shams | Apparatus, method, and computer program product for determining confidence measures and combined confidence measures for assessing the quality of microarrays |
| EP1420248A3 (de) * | 2002-11-18 | 2004-05-26 | Schott Glas | Validiertes Design für Mikroarrays |
| US20040122708A1 (en) * | 2002-12-18 | 2004-06-24 | Avinash Gopal B. | Medical data analysis method and apparatus incorporating in vitro test data |
| US7490085B2 (en) | 2002-12-18 | 2009-02-10 | Ge Medical Systems Global Technology Company, Llc | Computer-assisted data processing system and method incorporating automated learning |
| WO2005028647A1 (ja) * | 2003-09-22 | 2005-03-31 | Kyoto University | 核酸プローブ、核酸チップ、標的核酸検出方法、薬剤スクリーニング方法、標的核酸検出装置及び遺伝子診断方法 |
| US20060004526A1 (en) * | 2004-07-01 | 2006-01-05 | Ambion, Inc. | System and method for processing results of a complex genetic test |
| US7811824B2 (en) | 2006-03-30 | 2010-10-12 | Randox Laboratories Limited | Method and apparatus for monitoring the properties of a biological or chemical sample |
| US20080131887A1 (en) | 2006-11-30 | 2008-06-05 | Stephan Dietrich A | Genetic Analysis Systems and Methods |
| GB2444410B (en) * | 2006-11-30 | 2011-08-24 | Navigenics Inc | Genetic analysis systems and methods |
| EP2186031A4 (en) * | 2007-07-23 | 2014-03-26 | Fio Corp | A method and system for collating, storing, analyzing and enabling access to collected and analyzed data associated with biological and environmental test subjects |
| US9953137B2 (en) | 2012-07-06 | 2018-04-24 | Nant Holdings Ip, Llc | Healthcare analysis stream management |
| JP6707081B2 (ja) * | 2014-10-22 | 2020-06-10 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | 正の選択下で遺伝子を同定する方法 |
| CA2967013C (en) * | 2014-11-06 | 2023-09-05 | Ancestryhealth.Com, Llc | Predicting health outcomes |
| WO2018060365A1 (en) * | 2016-09-29 | 2018-04-05 | Koninklijke Philips N.V. | Genomic variant ranking system for clinical trial matching |
| JP6499344B2 (ja) * | 2018-03-23 | 2019-04-10 | Kddi株式会社 | 検査結果管理装置、及び検査結果管理方法 |
| CN109583289A (zh) * | 2018-09-27 | 2019-04-05 | 中国农业大学 | 蟹的性别识别方法和装置 |
| JP7143743B2 (ja) * | 2018-11-30 | 2022-09-29 | 株式会社島津製作所 | 分析システム、分析装置および情報処理方法 |
| JP6777351B2 (ja) * | 2020-05-28 | 2020-10-28 | 株式会社テンクー | プログラム、情報処理装置および情報処理方法 |
| US20230289569A1 (en) * | 2020-07-28 | 2023-09-14 | Xcoo, Inc. | Non-Transitory Computer Readable Medium, Information Processing Device, Information Processing Method, and Method for Generating Learning Model |
| CN112630173A (zh) * | 2020-12-04 | 2021-04-09 | 闪优智谱(厦门)检测科技有限公司 | 一种化学成分分析系统 |
| US20220208305A1 (en) * | 2020-12-24 | 2022-06-30 | Tempus Labs, Inc. | Artificial intelligence driven therapy curation and prioritization |
| US20230298690A1 (en) * | 2022-02-14 | 2023-09-21 | AiOnco, Inc. | Genetic information processing system with unbounded-sample analysis mechanism and method of operation thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5861242A (en) | 1993-06-25 | 1999-01-19 | Affymetrix, Inc. | Array of nucleic acid probes on biological chips for diagnosis of HIV and methods of using the same |
| US5692107A (en) * | 1994-03-15 | 1997-11-25 | Lockheed Missiles & Space Company, Inc. | Method for generating predictive models in a computer system |
| US5882933A (en) * | 1995-06-08 | 1999-03-16 | Coulter International Corp. | Method for determination of leukocytes and hemoglobin concentration in blood |
| US5733729A (en) | 1995-09-14 | 1998-03-31 | Affymetrix, Inc. | Computer-aided probability base calling for arrays of nucleic acid probes on chips |
| US6063026A (en) | 1995-12-07 | 2000-05-16 | Carbon Based Corporation | Medical diagnostic analysis system |
| US5936078A (en) * | 1995-12-12 | 1999-08-10 | Kyowa Hakko Kogyo Co., Ltd. | DNA and protein for the diagnosis and treatment of Alzheimer's disease |
| US5966712A (en) | 1996-12-12 | 1999-10-12 | Incyte Pharmaceuticals, Inc. | Database and system for storing, comparing and displaying genomic information |
| EP0972830A4 (en) * | 1997-02-21 | 2003-02-05 | Takara Shuzo Co | GENES ASSOCIATED WITH CANCER |
| EP1027459A1 (en) * | 1997-07-14 | 2000-08-16 | Abbott Laboratories | Telemedicine |
| US6188783B1 (en) * | 1997-07-25 | 2001-02-13 | Affymetrix, Inc. | Method and system for providing a probe array chip design database |
| WO1999041373A2 (en) * | 1998-02-11 | 1999-08-19 | Incyte Pharmaceuticals, Inc. | Human transport-associated molecules |
| US6004755A (en) | 1998-04-07 | 1999-12-21 | Incyte Pharmaceuticals, Inc. | Quantitative microarray hybridizaton assays |
| US6263287B1 (en) | 1998-11-12 | 2001-07-17 | Scios Inc. | Systems for the analysis of gene expression data |
-
2000
- 2000-08-28 WO PCT/US2000/023597 patent/WO2001016860A2/en not_active Ceased
- 2000-08-28 EP EP14168577.6A patent/EP2899660A1/en not_active Withdrawn
- 2000-08-28 CA CA2420717A patent/CA2420717C/en not_active Expired - Fee Related
- 2000-08-28 EP EP00957869.1A patent/EP1222602B1/en not_active Expired - Lifetime
- 2000-08-28 AU AU69427/00A patent/AU785341B2/en not_active Ceased
- 2000-08-28 NZ NZ518022A patent/NZ518022A/en not_active IP Right Cessation
- 2000-08-28 JP JP2001520734A patent/JP2003508853A/ja active Pending
-
2011
- 2011-06-15 JP JP2011133605A patent/JP2011238252A/ja active Pending
-
2014
- 2014-02-05 JP JP2014020747A patent/JP2014096183A/ja active Pending
-
2016
- 2016-04-22 JP JP2016086583A patent/JP5966109B1/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001016860A3 (en) | 2001-06-14 |
| EP1222602B1 (en) | 2015-12-09 |
| WO2001016860A2 (en) | 2001-03-08 |
| JP2003508853A (ja) | 2003-03-04 |
| JP2016154042A (ja) | 2016-08-25 |
| JP2011238252A (ja) | 2011-11-24 |
| JP2014096183A (ja) | 2014-05-22 |
| CA2420717A1 (en) | 2001-03-08 |
| NZ518022A (en) | 2004-01-30 |
| JP5966109B1 (ja) | 2016-08-10 |
| AU785341B2 (en) | 2007-01-25 |
| EP1222602A2 (en) | 2002-07-17 |
| AU6942700A (en) | 2001-03-26 |
| EP2899660A1 (en) | 2015-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2420717C (en) | Artificial intelligence system for genetic analysis | |
| CA2420717E (en) | Artificial intelligence system for genetic analysis | |
| US8693751B2 (en) | Artificial intelligence system for genetic analysis | |
| US20020183936A1 (en) | Method, system, and computer software for providing a genomic web portal | |
| US20030097222A1 (en) | Method, system, and computer software for providing a genomic web portal | |
| US20070087368A1 (en) | Method, System and Computer Software Providing a Genomic Web Portal for Functional Analysis of Alternative Splice Variants | |
| US20030120432A1 (en) | Method, system and computer software for online ordering of custom probe arrays | |
| US20030208454A1 (en) | Method and system for populating a database for further medical characterization | |
| US20030100995A1 (en) | Method, system and computer software for variant information via a web portal | |
| US20040126840A1 (en) | Method, system and computer software for providing genomic ontological data | |
| US20030104453A1 (en) | System for pharmacogenetics of adverse drug events | |
| US20040002818A1 (en) | Method, system and computer software for providing microarray probe data | |
| Castellino | When the chips are down | |
| WO2001056216A2 (en) | Method, system and computer software for providing a genomic web portal | |
| JP2003021630A (ja) | 臨床診断サービスを提供するための方法 | |
| NZ539578A (en) | Health and performance status determination of a biological subject using level, abundance or functional activity of a gene expression product in sample cells | |
| JP2004535612A (ja) | 遺伝子発現データの管理システムおよび方法 | |
| Markowitz et al. | Applying data warehouse concepts to gene expression data management | |
| US20040138821A1 (en) | System, method, and computer software product for analysis and display of genotyping, annotation, and related information | |
| US20060259251A1 (en) | Computer software products for associating gene expression with genetic variations | |
| JP2003526133A (ja) | 発現データ・マイニング・データベースおよび実験室情報管理を提供する方法および装置 | |
| Weyn-Vanhentenryck | The INIA Texas Gene Expression Database: An online tool for alcohol genomics | |
| Brazma | Minimum information about a microarray experiment. | |
| WO2002091110A2 (en) | Method, system and computer software for providing a genomic web portal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20190828 |